相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polymorphisms in Rv3806c (ubiA) and the upstream region of embA in relation to ethambutol resistance in clinical isolates of Mycobacterium tuberculosis from North India
Astha Giri et al.
TUBERCULOSIS (2018)
A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis
S. M. Ramirez-Busby et al.
SCIENTIFIC REPORTS (2017)
Predicting tuberculosis treatment outcome using metabolomics
Laneke Luies et al.
BIOMARKERS IN MEDICINE (2017)
New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis
Du Toit Loots
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol
Mrinal Kumar Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Ameeruddin Nusrath Unissa et al.
INFECTION GENETICS AND EVOLUTION (2016)
Rifampin Resistance Mutations Are Associated with Broad Chemical Remodeling of Mycobacterium tuberculosis
Nivedita Lahiri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
PharmGKB summary: isoniazid pathway, pharmacokinetics
Daniel J. Klein et al.
PHARMACOGENETICS AND GENOMICS (2016)
Isoniazid metabolism and hepatotoxicity
Pengcheng Wang et al.
ACTA PHARMACEUTICA SINICA B (2016)
Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates
Sarah M. Ramirez-Busby et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers
Roshan Kumar Sahu et al.
CURRENT DRUG METABOLISM (2015)
Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering
Pietro Alifano et al.
JOURNAL OF BIOTECHNOLOGY (2015)
ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis
Lei He et al.
TUBERCULOSIS (2015)
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review
Marva Seifert et al.
PLOS ONE (2015)
Metabolomics: Applications and Promise in Mycobacterial Disease
Mehdi Mirsaeidi et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2015)
An Altered Mycobacterium tuberculosis Metabolome Induced by katG Mutations Resulting in Isoniazid Resistance
Du Toit Loots
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Association between pncA Gene Mutations, Pyrazinamidase Activity, and Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis
Akio Aono et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Role of CYP3A in Isoniazid Metabolism In Vivo
Ke Liu et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?
Anastasia Koch et al.
EMERGING MICROBES & INFECTIONS (2014)
Study of the Rifampin Monoresistance Mechanism in Mycobacterium tuberculosis
Yu Pang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Global Metabolomics and Targeted Steroid Profiling Reveal That Rifampin, a Strong Human PXR Activator, Alters Endogenous Urinary Steroid Markers
Bora Kim et al.
JOURNAL OF PROTEOME RESEARCH (2013)
Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes
Hassan Safi et al.
NATURE GENETICS (2013)
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy
Feng Li et al.
NATURE MEDICINE (2013)
New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa
I. du Preez et al.
TUBERCULOSIS (2013)
Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis
Shuo Zhang et al.
EMERGING MICROBES & INFECTIONS (2013)
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Vidyasagar Ramappa et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2013)
Using Metabolomics for Elucidating the Mechanisms Related to Tuberculosis Treatment Failure
Laneke de Villiers et al.
CURRENT METABOLOMICS (2013)
A Novel Metabolite of Antituberculosis Therapy Demonstrates Host Activation of Isoniazid and Formation of the Isoniazid-NAD+ Adduct
Sebabrata Mahapatra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Upregulation of the Phthiocerol Dimycocerosate Biosynthetic Pathway by Rifampin-Resistant, rpoB Mutant Mycobacterium tuberculosis
Gregory P. Bisson et al.
JOURNAL OF BACTERIOLOGY (2012)
Pharmacometabonomic Characterization of Xenobiotic and Endogenous Metabolic Phenotypes That Account for Inter-individual Variation in Isoniazid-Induced Toxicological Response
Katharine Cunningham et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Altered Fatty Acid Metabolism Due to Rifampicin-Resistance Conferring Mutations in the rpoB Gene of Mycobacterium tuberculosis: Mapping the Potential of Pharmaco-metabolomics for Global Health and Personalized Medicine
Ilse du Preez et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment
Miles Trupp et al.
PLOS ONE (2012)
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine
Akinori Nakajima et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I
Halimah Sayahi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Metabolomic Analysis Reveals Novel Isoniazid Metabolites and Hydrazones in Human Urine
Feng Li et al.
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs
Pedro Eduardo Almeida Da Silva et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Wanliang Shi et al.
SCIENCE (2011)
Chemometrics in metabolomics-A review in human disease diagnosis
Rasmus Madsen et al.
ANALYTICA CHIMICA ACTA (2010)
An Integrated Metabolomics and Pharmacokinetics Strategy for Multi-Component Drugs Evaluation
Ke Lan et al.
CURRENT DRUG METABOLISM (2010)
Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs
Marcos Abdo Arbex et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2010)
Mutations at embB Codon 306 Are an Important Molecular Indicator of Ethambutol Resistance in Mycobacterium tuberculosis
Angela M. Starks et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India
G. P. S. Jadaun et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation
Joo-Youn Cho et al.
JOURNAL OF LIPID RESEARCH (2009)
Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis
Suhail Ahmad et al.
RESPIRATORY MEDICINE (2009)
Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity
Yukitaka Yoshikawa et al.
TOXICOLOGY IN VITRO (2009)
Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride
C. Becker et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli
Oren Zimhony et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
HMDB: the human metabolome database
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2007)
Mechanisms of action of isoniazid
Graham S. Timmins et al.
MOLECULAR MICROBIOLOGY (2006)
An official ATS statement: Hepatotoxicity of antituberculosis therapy
Jussi J. Saukkonen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The competitive cost of antibiotic resistance in Mycobacterium tuberculosis
Sebastien Gagneux et al.
SCIENCE (2006)
Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the β-subunit rifampin regions I and II
N Zenkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Rifamycin-mode of action, resistance, and biosynthesis
HG Floss et al.
CHEMICAL REVIEWS (2005)
Mass spectrometry in metabolome analysis
SG Villas-Boas et al.
MASS SPECTROMETRY REVIEWS (2005)
Early prediction of drug metabolism and toxicity: systems biology approach and modeling
A Bugrim et al.
DRUG DISCOVERY TODAY (2004)
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase:: Adduct affinity and drug resistance
R Rawat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid
Y Zhang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I
HI Boshoff et al.
JOURNAL OF BACTERIOLOGY (2002)
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide
Y Zhang et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2002)
Metabolomics - the link between genotypes and phenotypes
O Fiehn
PLANT MOLECULAR BIOLOGY (2002)
Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats
K Shibata et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2001)
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
O Zimhony et al.
NATURE MEDICINE (2000)
分享论文
